Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Durata Prices IPO Of 7.5 Mln Shares At $9.00/shr, Before Underwriting Discounts

RELATED NEWS
Trade DRTX now with 

Durata Therapeutics (DRTX: Quote) announced the pricing of its initial public offering of 7.5 million shares of common stock at a public offering price of $9.00 per share, before underwriting discounts.

The shares are scheduled to commence trading on the NASDAQ Global Market on July 19, 2012 under the ticker symbol "DRTX", noted the company.

Durata further stated that the underwriters have an option for a period of 30 days to buy up to an additional 1.13 million shares of common stock from the company at the public offering price, less the underwriting discount. The offering is expected to close on or about July 24, 2012.

Click here to receive FREE breaking news email alerts for Durata Therapeutics and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Friday after initially showing a lack of direction. The gains on the day extended the recent upward trend by the markets, with the tech-heavy Nasdaq reaching its best closing level in almost a month. Looking to capitalize on news of an Ebola diagnosis in New York City, Republican Senate candidate Scott Brown issued a statement Friday criticizing his Democratic opponent Sen. Jeanne Shaheen, D-N.H., for "waffling" on a travel ban. In another troubling sign for Democrats, the results of a Gallup poll released on Friday show that Tea Party Republicans are much more motivated to vote in the upcoming midterm elections than other Americans. The poll found that 73 percent of Tea Party Republicans are "extremely" or "very" motivated to vote in this year's elections.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.